Boston Scientific Q2 Earnings: Strong Performance Of Cardiovascular Devices Leads To 2024 Guidance Hike Again
Boston Scientific Q2 Earnings: Strong Performance Of Cardiovascular Devices Leads To 2024 Guidance Hike Again
Boston Scientific Corporation (NYSE:BSX) generated second-quarter revenues of $4.12 billion, beating the consensus estimate of $4.02 billion.
波士顿科学公司（纽交所：BSX）第二季度营收为412亿美元，超过共识预估的402亿美元。
Sales increased 14.5% on a reported basis, compared to the company's guidance range of 10.5%-12.5% and 16.1% on an operational basis, 14.7% on an organic basis, compared to the company's guidance range of 10%-12%.
报告显示，公司营收按报告基础增长14.5%，比公司指导范围10.5%-12.5%高；按运营基础增长16.1%，按有机基础增长14.7%，比公司指导范围10%-12%高。
The company earned an adjusted EPS of $0.62, beating the consensus of $0.58 and the management guidance of $0.57-$0.59.
公司调整后每股收益为0.62美元，超过了预期的0.58美元和管理层预期的0.57美元至0.59美元。
Related: Boston Scientific's Upside With Cardiology Devices Drives Momentum.
相关报道：波士顿科学的心脏病诊断设备存在增长空间。
The company's cardiovascular segment generated sales of $2.64 billion, rising 17.8% (19.7% operationally and 19% organically).
该公司心血管事业部销售额达到了264亿美元，增长了17.8%（运营基础和有机基础均为19.7%和19%）。
Boston Scientific reported 20.1% growth for cardiology products and 10.2% growth in peripheral interventions.
波士顿科学的心脏病产品增长了20.1%，周边介入术增长了10.2%。
MedSurg segment revenues increased 9% to $1.48 billion (10.1% operationally and 7.6% organically).
医疗手术事业部营收增长9%，达到了148亿美元（运营基础和有机基础分别增长10.1%和7.6%）。
Neuromodulation led the way with a 15.5% increase. Urology (8.2%) and Endoscopy (7.1%) followed.
神经调控市场领先，增长了15.5%。其次是泌尿外科（8.2%）和内窥镜（7.1%）。
Outlook: Boston Scientific forecasts net sales growth for 2024 of approximately 13.5%-14.5% on a reported basis and 13%-14% on an organic basis, compared to prior guidance of 11%-13% and 10%-12%, respectively.
展望：波士顿科学公司预计2024年营收按报告基础将增长约13.5%-14.5%，有机基础将增长13%-14%，超过先前预期的分别为11%-13%和10%-12%。
Boston Scientific estimates 2024 adjusted EPS of $2.38-$2.42 compared to prior guidance of $2.29-$2.34 and consensus of $2.33.
波士顿科学公司预计2024年调整后每股收益为2.38-2.42美元，高于先前预期的2.29-2.34美元及市场预估的2.33美元。
For the third quarter, the company estimates net sales growth of 13%-14% on a reported and organic basis.
第三季度，公司预计营收按报告和有机基础增长13%-14%。
The company forecasts adjusted EPS of $0.57-$0.59 versus a consensus of $0.57.
公司预计调整后每股收益为0.57-0.59美元，市场预估为0.57美元。
Price Action: BSX stock was trading lower by 1.95% at $77.05 at the last check on Wednesday.
周三最新数据显示，BSX股票下跌1.95%，报收77.05美元。
- Boston Scientific Adds Stroke Prevention To Vascular Portfolio Via Silk Road Medical's $1.3B Deal.
- 通过对Silk Road Medical的13亿美元收购，波士顿科学将卒中预防产品并入血管产品系列。
Photo via Shutterstock
图片来自shutterstock。